Monthly News Roundup - June 2022

Skyrizi Approved with On-Body Injector for Treatment of Crohn’s disease Skyrizi (risankizumab-rzaa) works to reduce inflammation by binding to excess interleukin-23 (IL-23), a cytokine involved in several immune-mediated conditions. In June,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news